Abstract:
The paper reports on a study which examined all new single chemical entities introduced on to the British prescription medicine market between 1962 and 1970. The therapeutic novelty and value of each at the time of product launch was assessed by a panel of consultant physicians on a ranking scale of 1 to 5. The commercial success of each was gauged by the market share achieved in the first two or three years of life.